Safety of Riluzole in Patients With Acute Spinal Cord Injury

Summary

The purpose of the study is to find out if the use of the drug Riluzole is both safe and improves outcome in patients with acute traumatic spinal cord injury (SCI).

Conditions

• Spinal Cord Injury

Interventions

DRUG

Riluzole

50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).

Sponsors & Collaborators

• Christopher Reeve Paralysis Foundation

  collaborator OTHER

• United States Department of Defense

  collaborator FED

• AO Clinical Investigation and Publishing Documentation

  collaborator OTHER

• Ontario Neurotrauma Foundation

  collaborator OTHER

• The Methodist Hospital Research Institute

  lead OTHER

Principal Investigators

• Robert G Grossman, MD · The Methodist Hospital Research Institute

• Michael Fehlings, MD, PhD · University of Toronto/Toronto Western Hospital, Toronto

• Michele M Johnson, MD · the University of Houston/Memorial HermannHospital, Houston

• Christopher Shaffery, MD · University of Virginia Health System, Charlottesville

• Susan Harkema, PhD · University of Louisville, Louisville

• Bizhan Aarabi, MD · University of Maryland Medical Center, Baltimore

• James Harrop, MD · Thomas Jefferson University, Philadelphia

• James Guest, MD, PhD · University of Miami, Miami

• Ralph Frankowski, PhD · The University of Texas School of Public Health, Houston

• Diana Chow, PhD · University of Houston, College of Pharmacy, Houston

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-04-30

Primary Completion

2011-06-30

Completion

2012-04-30

Countries

• United States
• Canada

Study Locations